title: New strategies with anti-IgE in allergic diseases.
abstract: IgE has long been known as a therapeutic target for allergic disease, but the difficulty has been in selecting agents that don't trigger cross linkage of IgE when bound to its high affinity receptor (FceR1) on mast cells and basophils. By "designing" a monoclonal antibody (mAb) which targets that part of IgE that binds to that binds to the a-chain of FceR1, the allergic cascade can be effectively interrupted and diseases such as asthma greatly improved, providing a substantial part of their phenotype engages IgE. Clinical trials and real life studies confirm this. Beyond asthma, a whole range of other diseases dependent upon IgE initiation and triggering are being identified. These diseases are now being explored as being amenable to anti-IgE therapy some of which are comorbidities of asthma and others not. The advent of an even more potent anti-IgE mAb - QGE031 - is creating further opportunities for anti-IgE therapy to improve the lives of so many people with IgE-related diseases.
authors.affiliation: Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton General Hospital, Mail point 810, Level F, South Block, Southampton SO166YD, UK.
authors.forename: Stephen T
authors.initials: ST
authors.lastname: Holgate
keywords: Allergy; Anti-IgE monoclonal antibody; Asthma; Comorbidity; Omalizumab
references.citation: Allergy Asthma Clin Immunol. 2010 Dec 03;6(1):32
references.pmid: 21129189
references.citation: Allergy. 2009 Jan;64(1):72-80
references.pmid: 19076931
references.citation: Int Arch Allergy Immunol. 2006;139(2):122-31
references.pmid: 16374021
references.citation: J Allergy Clin Immunol. 2001 Aug;108(2 Suppl):S65-71
references.pmid: 11498675
references.citation: Respir Med. 2007 Jul;101(7):1483-92
references.pmid: 17339107
references.citation: BMC Immunol. 2013 Dec 13;14:54
references.pmid: 24330349
references.citation: Expert Opin Biol Ther. 2013 May;13(5):765-77
references.pmid: 23517576
references.citation: J Allergy Clin Immunol. 2010 Apr;125(4):896-901.e6
references.pmid: 20132969
references.citation: Int Arch Allergy Appl Immunol. 1989;88(1-2):23-8
references.pmid: 2523358
references.citation: J Immunol. 1966 Dec;97(6):840-53
references.pmid: 4163008
references.citation: J Allergy Clin Immunol. 2004 Sep;114(3):700-4
references.pmid: 15356577
references.citation: Arch Dis Child. 2012 Jul;97(7):604-9
references.pmid: 22685051
references.citation: Clin Exp Allergy. 2014 Nov;44(11):1371-85
references.pmid: 25200415
references.citation: Ann Am Thorac Soc. 2014 Feb;11 Suppl 2:S105-11
references.pmid: 24559022
references.citation: Drugs. 2001;61(2):253-60; discussion 261
references.pmid: 11270941
references.citation: J Allergy Clin Immunol. 2014 Sep;134(3):560-567.e4
references.pmid: 24679845
references.citation: Curr Opin Immunol. 1997 Dec;9(6):805-13
references.pmid: 9492982
references.citation: J Allergy Clin Immunol. 2004 Dec;114(6):1472-4
references.pmid: 15577855
references.citation: J Clin Invest. 1997 Mar 1;99(5):879-87
references.pmid: 9062345
references.citation: N Engl J Med. 2013 Mar 7;368(10):924-35
references.pmid: 23432142
references.citation: Ann Allergy Asthma Immunol. 2012 Jul;109(1):59-64
references.pmid: 22727159
references.citation: Respiration. 2012;83(6):520-8
references.pmid: 22236804
references.citation: N Engl J Med. 2011 Mar 17;364(11):1005-15
references.pmid: 21410369
references.citation: Trends Mol Med. 2013 Aug;19(8):501-12
references.pmid: 23831338
references.citation: Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):475-84
references.pmid: 22697079
references.citation: Evid Based Med. 2014 Aug;19(4):135
references.pmid: 24627175
references.citation: Cochrane Database Syst Rev. 2014 Jan 13;(1):CD003559
references.pmid: 24414989